ABSTRACT
SAD
ADVERSE EVENT, GRAM-POSITIVE BACTERIAL INFECTIONS
Hailin Wang, Hong Yuan and Huahui Yang are full-time employees of Shanghai MicuRx Pharmaceutical Co., Ltd. Other authors declare no competing interests.Contezolid acefosamil (also known as MRX-4), a prodrug of contezolid, is under development for treatment of multidrug-resistant Gram-positive bacterial infections. A phase I single ascending dose (SAD) and multiple-dose placebo-controlled study was conducted to assess the safety, tolerability, and pharmacokinetics (PK) of contezolid acefosamil in healthy Chinese subjects following intravenous (IV) and oral administration. Adverse events (AEs) and PK parameters were assessed appropriately. All subjects (